Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02574533
Title Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Gradalis, Inc.
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Texas Oncology P.A., Texas Cancer Center Abilene Texas 79606 United States Details
Mary Crowley Medical Research Centers Dallas Texas 75230 United States Details
Cancer Care Northwest Spokane Washington 99202 United States Details
*Shaded cells indicate that there was no data available from for the field